Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC)

Hepatocellular carcinoma (HCC) remains a significant clinical challenge with few therapeutic options. Genomic amplification and/or overexpression of the MYC oncogene is a common molecular event in HCC, thus making it an attractive target for drug therapy. Unfortunately, currently there are no direct...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhanasekaran, Renumathy, Gabay-Ryan, Meital, Baylot, Virginie, Lai, Ian, Mosley, Adriane, Huang, Xinqiang, Zabludoff, Sonya, Li, Jian, Kaimal, Vivek, Karmali, Priya, Felsher, Dean W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814155/
https://www.ncbi.nlm.nih.gov/pubmed/29464015
http://dx.doi.org/10.18632/oncotarget.22342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814155/
https://www.ncbi.nlm.nih.gov/pubmed/29464015
http://dx.doi.org/10.18632/oncotarget.22342

Ejemplares similares